A consistent pattern in medical training is hard to ignore: many students enter wanting to work in primary care with underserved groups, yet later choose to pursue specialty careers. I’d…
Another Elevidys trial, FDA reconsiders peptides, and other biotech news from The Readout
The FDA will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain peptides
By MATTHEW HOLT & CLAUDE You’ll recall that a few weeks back I gave Claude some prompts and my entire corpus of work on THCB and asked it to write…
A Michigan State University expert examines whether social media meets clinical addiction standards and what research and the APA still need to resolve
Revolution Medicines $2B fundraise, Structure's new hire hints at acquisition efforts, and more Readout biotech news
The FDA asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill, Foundayo
When scientific journals publish expressions of concerns, they have an obligation to do so prominently, Ed Silverman writes.
The key health care issues we're watching as Congress returns from recess.
Ben Sasse on enrolling in Rev Med's drug trial, more ADC investment, and other biotech news from The Readout